Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Bepirovirsen in Hepatic Impairment
NCT04971928Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (3 arms), sponsored by GSK. Primary endpoints: Area under the concentration-time curve from time zero extrapolated to infinite time at Day 50 and Maximum observed concentration at Day 50. Started Sep 2021; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04971928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971928.